Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial
- Christina H. Ruhlmann*
- , Thomas Broe Christensen
- , Line Hammer Dohn
- , Merete Paludan
- , Eva Rønnengart
- , Ulrich Halekoh
- , Felix Hilpert
- , Petra Feyer
- , Gunnar Kristensen
- , Olfred Hansen
- , Dorothy Keefe
- , Jørn Herrstedt
*Corresponding author af dette arbejde
Publikation: Bidrag til tidsskrift › Artikel › Forskning › peer review